Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SCHOTT Doubles its Production Capacity for SCHOTT TopPac® Polymer Syringes

Published: Tuesday, April 30, 2013
Last Updated: Monday, April 29, 2013
Bookmark and Share
Company to offer customers a greater degree of flexibility and ensure supply security.

To address the increasing global demand for prefillable polymer syringes, SCHOTT is currently expanding its manufacturing capacity for small size (1 to 10 ml) SCHOTT TopPac® syringes.

A new production line installed at the SCHOTT site in St. Gallen, Switzerland, expanded the existing production capacity by 100% from April onwards.

This enables SCHOTT to offer customers a greater degree of flexibility and ensure supply security.

SCHOTT is a pioneer in establishing the SCHOTT TopPac® product range as ready-to-fill syringes, which are made of Cyclic Olefin Copolymer (COC).

Over the past 15 years, SCHOTT made significant investments to develop and industrialize COC material for pharmaceutical containers for injectable drugs.

COC is an inert material and the SCHOTT TopPac® syringe system is designed to be compatible with a broad range of drugs. The excellent barrier properties of the SCHOTT TopPac® syringe system allow long term storage of drugs even in small syringe sizes.

In addition, SCHOTT TopPac® syringes have a glass-like transparency, and are break resistant and lightweight.

SCHOTT TopPac® syringes are available in the range from 1ml to 50ml with cross linked silicone for optimal functionality.

Pharmaceutical companies benefit from the fact that SCHOTT TopPac® syringes are manufactured in clean rooms with a fully automated process starting from injection-molding to the final packaging in nest and tub. The syringes are sterilized and are ready for aseptic filling operations.

SCHOTT intends to achieve further growth in the field of polymer and glass syringes and also underscores its commitment to offer ideal product solutions to pharmaceutical companies - today and tomorrow.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCHOTT Announces Major Expansion of Pharmaceutical Packaging Manufacturing in Russia
Capacity to expand by more than 50 percent / Consistent investment strategy helps customers achieve growth and quality objectives.
Monday, November 26, 2012
Scientific News
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Dissecting Bacterial Infections at the Single-Cell Level
Researchers have used single-cell analysis technology to provide new insight into the Salmonella infection process.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!